

# China Respiration System Chemical Medicine Industry Competitive Landscape and Leading Enterprise Research Report, 2013-2017

## 目 录

### CONTENTS

#### Chapter 1: Development Overview of China Respiratory System Chemical Medicine Industry

##### 1.1 Concept of Respiratory System Chemical Medicine Industry

- 1.1.1 Definition of Respiratory System Chemical Medicine Industry
- 1.1.2 Scope Definition of Report on Respiratory System Chemical Medicine Industry
- 1.1.3 Analysis System for Report on Respiratory System Chemical Medicine Industry

##### 1.2 Features of Respiratory System Chemical Medicine Industry

- 1.2.1 Development Features of Respiratory System Chemical Medicine Industry
- 1.2.2 Influencing Factors of Respiratory System Chemical Medicine Industry

##### 1.3 Policy Environment for Respiratory System Chemical Medicine Industry

- 1.3.1 Introduction and Explanation of Policies Related to Respiratory System Chemical Medicine Industry
- 1.3.2 Introduction and Explanation of Plans Related to Respiratory System Chemical Medicine Industry

#### Chapter 2: Development of Respiratory System Chemical Medicine Industry

##### 2.1 Development Overview of Chemical and Pharmaceutical Industry

- 2.1.1 Development Overview of International Chemical and Pharmaceutical Industry
- 2.1.2 Development Overview of International Chemical and Pharmaceutical Industry
  - (1) Operation of Industry
  - (2) Industry Scale
  - (3) Competitive Landscape
  - (4) Trend Outlook

##### 2.2 Development Overview of Respiratory System Chemical Medicine Industry

- 2.2.1 Concept and Classification of Industry
- 2.2.2 Operation of Industry
- 2.2.3 Market Scale of Industry
- 2.2.4 Development Trend for Industry
  - (1) Demand Forecast for Respiratory Drugs Industry
  - (2) Development Trend for Respiratory Drugs Industry

#### Chapter 3: Analysis of Competition for Nasal Spray Market Segments

##### 3.1 Development Overview of Nasal Spray

##### 3.2 Competition for Major Nasal Sprays

##### 3.3 Nasal Spray Manufacturing Enterprises Compete for Position

##### 3.4 Competition for Major Nasal Sprays in Domestic

- 3.4.1 Azelastine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 3.4.2 Mometasone
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 3.4.3 Oxymetazoline
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets

- (4) Drug Market Demand Trend
- 3.4.4 Levocabastine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 3.4.5 Xylometazoline
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend

### 3.5 Competition Trend for Nasal Spray

## Chapter 4: Analysis of Competition for Throat Preparation Market Segments

- 4.1 Development Overview of Throat Preparation
- 4.2 Competition for Major Throat Preparations
- 4.3 Throat Preparation Manufacturing Enterprises Compete for Position
- 4.4 Competition for Major Throat Preparations in Domestic

- 4.4.1 Dequalinium Chloride
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 4.4.2 Cydiodine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 4.4.3 Cetrimide/ Benzalkonium Chloride
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 4.4.4 Lidocaine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend

### 4.5 Competition Trend for Throat Preparation

## Chapter 5: Analysis of Competition for Anti-asthmatic Drug Market Segments in Domestic

- 5.1 Development Overview of Anti-asthmatic Drug
- 5.2 Competition for Anti-asthmatic Drugs
- 5.3 Anti-asthmatic Drug Manufacturing Enterprises Compete for Position
- 5.4 Competition for Major Anti-asthmatic Drugs in Domestic

- 5.4.1 Budesonide
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 5.4.2 Salmeterol/Fluticasone
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 5.4.3 Doxofylline
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 5.4.4 Montelukast

- (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 5.4.5 Compound Methoxyphenamine Hydrochloride
- (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 5.4.6 Budesonide/Formoterol
- (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend

#### 5.5 Competition Trend for Anti-asthmatic Drug

### Chapter 6: Analysis of Competition for Cough and Cold Medicine Market Segments in Domestic

- 6.1 Development Overview of Cough and Cold Medicine
- 6.2 Competition for Cough and Cold Medicines
- 6.3 Cough and Cold Medicine Manufacturing Enterprises Compete for Position
- 6.4 Competition for Major Cough and Cold Medicines in Domestic

- 6.4.1 Ambroxol
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 6.4.2 Bromhexine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 6.4.3 Acetylcysteine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 6.4.4 Eucalyptol/ Limonene and Pinene
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend

#### 6.5 Competition Trend for Cough and Cold Medicine

### Chapter 7: Analysis of Competition for Antihistamines Market Segments in Domestic

- 7.1 Development Overview of Antihistamines
- 7.2 Competition for Antihistamines
- 7.3 Antihistamines Manufacturing Enterprises Compete for Position
- 7.4 Competition for Major Antihistamines in Domestic

- 7.4.1 Loratadine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 7.4.2 Cetirizine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 7.4.3 Desloratadine
  - (1) Basic Information

- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend
- 7.4.4 Mizolastine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 7.4.5 Levocetirizine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 7.4.6 Ebastine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 7.4.7 Epinastine
  - (1) Basic Information
  - (2) Competition Position for Major Manufacturing Enterprises
  - (3) Competitive Landscape of Regional Drug Markets
  - (4) Drug Market Demand Trend
- 7.5 Competition Trend for Antihistamines

## Chapter 8: Analysis of Competition for Other Domestic Respiratory System Medicines Market

- 8.1 Development Overview of Other Respiratory System Medicines
- 8.2 Competitive Landscape for Other Major Respiratory System Medicines
- 8.3 Competitive Position of Other Respiratory System Medicine Manufacturing Corporations
- 8.4 Competition for Parts of Other Respiratory System Medicines
  - 8.4.1 Pulmonary Surfactant
    - (1) Basic Information
    - (2) Competition Position for Major Manufacturing Enterprises
    - (3) Competitive Landscape of Regional Drug Markets
    - (4) Drug Market Demand Trend
  - 8.4.2 Dermatophagoides Farinae
    - (1) Basic Information
    - (2) Competition Position for Major Manufacturing Enterprises
    - (3) Competitive Landscape of Regional Drug Markets
    - (4) Drug Market Demand Trend
  - 8.4.3 Calf Pulmonary Surfactant
    - (1) Basic Information
    - (2) Competition Position for Major Manufacturing Enterprises
    - (3) Competitive Landscape of Regional Drug Markets
    - (4) Drug Market Demand Trend

## Chapter 9: Analysis of Leading Enterprises in Respiratory System Chemical Medicine Industry

- 9.1 Overall Situation of Respiratory System Chemical Medicine Manufacturing Enterprises
  - 9.1.1 Comprehensive Overview of Respiratory System Chemical Medicine Manufacturing Enterprises
  - 9.1.2 Sales Ranking of Respiratory System Chemical Medicine Manufacturing Enterprises
  - 9.1.3 Total Profit Ranking of Respiratory System Chemical Medicine Manufacturing Enterprises
- 9.2 Leading Brands in Respiratory System Chemical Medicine Manufacturing Enterprises and Their Investment Layout in China
  - 9.2.1 Pfizer
    - (1) Development Profile
    - (2) Sales Network
    - (3) Product Structure
    - (4) Operation Situation
    - (5) Operation Situation of Pfizer Dalian Plant
      - 1) Profile

- 2) Production and Marketing Capability
  - 3) Profitability
  - 4) Operation Capability
  - 5) Debt-paying Ability
  - 6) Development Capability
- 9.2.2 Novartis AG
- (1) Development Profile
  - (2) Sales Network
  - (3) Product Structure
  - (4) Operation Situation
  - (5) Operation Situation of Beijing Novartis Pharma Ltd.
    - 1) Profile
    - 2) Production and Marketing Capability
    - 3) Profitability
    - 4) Operation Capability
    - 5) Debt-paying Ability
    - 6) Development Capability
- 9.2.3 Merck
- (1) Development Profile
  - (2) Sales Network
  - (3) Product Structure
  - (4) Operation Situation
  - (5) Operation Situation of Hangzhou Moshadong Pharmaceutical Co., Ltd.
    - 1) Profile
    - 2) Production and Marketing Capability
    - 3) Profitability
    - 4) Operation Capability
    - 5) Debt-paying Ability
    - 6) Development Capability
  - (6) Operation Situation of Shanghai Schering-Plough Co., Ltd.
    - 1) Profile
    - 2) Production and Marketing Capability
    - 3) Profitability
    - 4) Operation Capability
    - 5) Debt-paying Ability
    - 6) Development Capability
- 9.2.4 Sanofi
- (1) Development Profile
  - (2) Sales Network
  - (3) Product Structure
  - (4) Operation Situation
  - (5) Operation Situation of Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
    - 1) Profile
    - 2) Production and Marketing Capability
    - 3) Profitability
    - 4) Operation Capability
    - 5) Debt-paying Ability
    - 6) Development Capability
- 9.2.5 Roche Holding Ltd.
- (1) Development Profile
  - (2) Sales Network
  - (3) Product Structure
  - (4) Operation Situation
  - (5) Operation Situation of Shanghai Roche Pharmaceutical Ltd.
    - 1) Profile
    - 2) Production and Marketing Capability
    - 3) Profitability
    - 4) Operation Capability
    - 5) Debt-paying Ability

- 6) Development Capability
- 9.2.6 Glaxo Smith Kline
  - (1) Development Profile
  - (2) Sales Network
  - (3) Product Structure
  - (4) Operation Situation
  - (5) Operation Situation of Shanghai Glaxosmithkline Biological Products Co., Ltd.
    - 1) Profile
    - 2) Production and Marketing Capability
    - 3) Profitability
    - 4) Operation Capability
    - 5) Debt-paying Ability
    - 6) Development Capability
- 9.2.7 AstraZeneca
  - (1) Development Profile
  - (2) Sales Network
  - (3) Product Structure
  - (4) Operation Situation
  - (5) Operation Situation of Jiangsu AstraZeneca Co., Ltd.
    - 1) Profile
    - 2) Production and Marketing Capability
    - 3) Profitability
    - 4) Operation Capability
    - 5) Debt-paying Ability
    - 6) Development Capability
- 9.2.8 Johnson & Johnson
  - (1) Development Profile
  - (2) Sales Network
  - (3) Product Structure
  - (4) Operation Situation
  - (5) Operation Situation of Xian Janssen Pharmaceutical Ltd.
    - 1) Profile
    - 2) Production and Marketing Capability
    - 3) Profitability
    - 4) Operation Capability
    - 5) Debt-paying Ability
    - 6) Development Capability
- 9.2.9 Eli Lilly
  - (1) Development Profile
  - (2) Sales Network
  - (3) Product Structure
  - (4) Operation Situation
  - (5) Operation Situation of Eli Lilly and Company
    - 1) Profile
    - 2) Production and Marketing Capability
    - 3) Profitability
    - 4) Operation Capability
    - 5) Debt-paying Ability
    - 6) Development Capability
- 9.2.10 Boehringer Ingelheim
  - (1) Development Profile
  - (2) Sales Network
  - (3) Product Structure
  - (4) Operation Situation
  - (5) Operation Situation of Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd.
    - 1) Profile
    - 2) Production and Marketing Capability
    - 3) Profitability
    - 4) Operation Capability

- 5) Debt-paying Ability
- 6) Development Capability

### 9.3 Case Study of Leading Enterprises of Domestic Respiratory System Chemical Medicine Industry

#### 9.3.1 Shenzhen Daphne Pharmaceuticals Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

#### 9.3.2 Changzhou Jinyuan Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

#### 9.3.3 China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

#### 9.3.4 Beijing Wellso Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

## 9.3.5 Heilongjiang Fuhe Huaxing Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

## 9.3.6 Reyoung Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

## 9.3.7 Southwest Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

## 9.3.8 Beijing Jiuhe Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

## 9.3.9 Jiangxi Kelun Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning



- (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
    - 1) Production and Marketing Capability
    - 2) Profitability
    - 3) Operation Capability
    - 4) Debt-paying Ability
    - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.10 Tianjin Pharmaceutical Research Institute Co., Ltd.
- (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
    - 1) Production and Marketing Capability
    - 2) Profitability
    - 3) Operation Capability
    - 4) Debt-paying Ability
    - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.11 Beijing Laneva Pharmaceutical Co., Ltd.
- (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
    - 1) Production and Marketing Capability
    - 2) Profitability
    - 3) Operation Capability
    - 4) Debt-paying Ability
    - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.12 ChongQing Carelife Pharmaceutical Co., Ltd.
- (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
    - 1) Production and Marketing Capability
    - 2) Profitability
    - 3) Operation Capability
    - 4) Debt-paying Ability
    - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.13 Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation

- 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.14 Hunan Jiudian Pharmaceutical Co., Ltd.
- (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.15 Guizhou Yunfeng Pharmaceutical Co., Ltd.
- (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.16 Shenzhen Haibin Pharmaceutical Co., Ltd.
- (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability
  - 4) Debt-paying Ability
  - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.17 Biochemical Pharmaceutical Factory of Zhuhai S.E.Z
- (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
  - 1) Production and Marketing Capability
  - 2) Profitability
  - 3) Operation Capability

- 4) Debt-paying Ability
- 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend
- 9.3.18 Changzhou Siyao Pharmaceuticals Co., Ltd.
  - (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
    - 1) Production and Marketing Capability
    - 2) Profitability
    - 3) Operation Capability
    - 4) Debt-paying Ability
    - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.19 Chongqing Huapont Pharm. Co., Ltd.
  - (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
    - 1) Production and Marketing Capability
    - 2) Profitability
    - 3) Operation Capability
    - 4) Debt-paying Ability
    - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.20 Yangtze River Pharmaceutical Group
  - (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
    - 1) Production and Marketing Capability
    - 2) Profitability
    - 3) Operation Capability
    - 4) Debt-paying Ability
    - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.21 Hainan Poly Pharm Co., Ltd.
  - (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
    - 1) Production and Marketing Capability
    - 2) Profitability
    - 3) Operation Capability
    - 4) Debt-paying Ability
    - 5) Development Capability
  - (6) Operational Advantages and Disadvantages

- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend
- 9.3.22 Beijing Double-Crane Pharmaceutical Co., Ltd.
  - (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
    - 1) Production and Marketing Capability
    - 2) Profitability
    - 3) Operation Capability
    - 4) Debt-paying Ability
    - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend
- 9.3.23 Jiangsu Nhwa Pharmaceutical Co., Ltd.
  - (1) Development Overview
  - (2) Product and Market Positioning
  - (3) Situation of Market Distribution
  - (4) Profile of Major Respiration System Drugs
  - (5) Overall Operation
    - 1) Production and Marketing Capability
    - 2) Profitability
    - 3) Operation Capability
    - 4) Debt-paying Ability
    - 5) Development Capability
  - (6) Operational Advantages and Disadvantages
  - (7) Investment, M&A and Restructuring
  - (8) Latest Development Trend

如需了解报告详细内容，请直接致电前瞻客服中心。

全国免费服务热线：400-068-7188 0755-82925195 82925295 83586158

或发电子邮件：[service@qianzhan.com](mailto:service@qianzhan.com)

或登录网站：<https://bg.qianzhan.com/>

我们会竭诚为您服务！